EP Patent
EP2474529B1 — Crystalline forms of an active pharmaceutical ingredient
Assigned to Sandoz AG · Expires 2014-05-14 · 12y expired
What this patent protects
Patent listed against Rezlidhia.
Drugs covered by this patent
- Rezlidhia (OLUTASIDENIB) · Rigel Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.